Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
In the landmark STEP 1 clinical trial, semaglutide produced an average weight loss of approximately 15% of body weight over 68 weeks of treatment
In comparison, the IGF1-LR3 peptide analog appears to have a higher affinity to the anabolic insulin-like growth factor 1 receptors and binds less to serum proteins
C.SaudubrayJ
Cagrilintide showed similar directional improvements, though the magnitude was generally proportional to the degree of weight loss rather than suggesting independent cardiovascular effects
US$ 27.26
US$ 26.81
US$ 29.06
